截至今日，新可来是中国首个且唯一获批的每月给药一次，用于治疗血嗜酸性粒细胞计数（BEC）≥150 细胞 /μL 的广泛COPD患者的生物制剂该获批是基于 MATINEE 和 METREX III ...

Clinical guidelines recommend long-acting bronchodilators as first maintenance therapy for chronic obstructive pulmonary disease (COPD), with inhaled corticosteroids (ICS) reserved for patients with ...

COPD inhaled triple therapy (BDP/FF/G) improved symptoms, lung function, adherence, and QOL in patients previously treated with inhaled dual therapy.

The benefits of pharmacotherapy with tiotropium HandiHaler 18 μg for patients with chronic obstructive pulmonary disease (COPD) have been previously demonstrated. However, few data exist regarding the ...

Changing patients from an inhaled corticosteroid (ICS)/long-acting β agonist (LABA) inhaler and long-acting muscarinic agonist (LAMA) inhaler to a LAMA/LABA inhaler and a separate ICS inhaler did not ...

(HealthDay News) — A combination drug therapy of long-acting beta agonists and inhaled corticosteroids appears to be the best treatment for older adults with chronic obstructive pulmonary disease ...

Key opinion leaders highlight the triple therapy approach from the most recent GOLD guidelines, including ICS, long-acting beta-agonist (LABA), and long-acting muscarinic antagonist (LAMA). Jeffrey D.

On Wednesday, the FDA approved Verona Pharma plc’s (NASDAQ:VRNA) Ohtuvayre (ensifentrine) for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients. Ohtuvayre is ...

Please provide your email address to receive an email when new articles are posted on . More time between an exacerbation and start of COPD triple therapy increased rate of future exacerbations.

Triple therapy delivered in a single inhaler reduces moderate to severe exacerbations in chronic obstructive pulmonary disease (COPD) to a greater extent than dual-inhaler therapy in patients at high ...

Triple therapy for COPD, vs ICS/LABA therapy, was independently associated with ischemic heart disease, heart failure, arrhythmia, and atrial fibrillation/flutter. Cardiovascular events in patients ...

Once-daily dosing with a very long-acting beta 2-agonist (VLABA) would be a significant convenience and compliance-enhancing advantage leading to improved clinical outcomes in patients with asthma and ...